Dawn Marie Stull Medical Science Liaison at Takeda Pharmaceuticals speaks about Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Link to Study:
https://www.futuremedicine.com/doi/10.2217/FON-2020-1225
Goal:
The aim of this study was to see whether ixazomib-lenalidomide-dexamethasone (IRd) was successful and healthy in relapsed/refractory multiple myeloma patients in routine clinical practice. Patients and procedures: Data from the INSIGHT MM global retrospective study and the Czech Registry of Monoclonal Gammopathies were combined and analyzed at the patient level. At the time of the data cut-off, 263 patients from 13 countries were included in the study. The median time from diagnosis to the start of IRd was 35.8 months, with a 14.8-month median follow-up period. Overall, 73% of patients responded, with a median progression-free survival of 21.2 months and a period until the next therapy of 33.0 months. In 17 percent/36 percent of patients, ixazomib/lenalidomide dose reductions were expected, and 32 percent/30 percent of patients discontinued ixazomib/lenalidomide due to adverse effects. Conclusion: In normal clinical practice, the efficacy and protection of IRd are similar to those recorded in TOURMALINE-MM1.
NCT02761187 is the number assigned to a clinical trial (ClinicalTrials.gov)
Lay Out Of Abstract
Multiple myeloma (MM), a blood cancer that grows from cells in the bone marrow, is treated with proteasome inhibitors. When administered in conjunction with two other oral medications, lenalidomide, and dexamethasone, to adult patients who have had one previous treatment, ixazomib is the first oral proteasome inhibitor to be approved for use in MM. In a review performed in normal clinical practice, we discovered that the efficacy and safety of ixazomib + lenalidomide + dexamethasone in previously treated MM patients are comparable to those shown in Phase III clinical trial that led to approval. These results are important because they show that, considering their poorer fitness, MM patients in the routine practice will reap the same gains from this procedure as patients in clinical trials.